A. Turner

发表

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Robert Brown, N. Tunariu, C. Yap, 2022, Journal for ImmunoTherapy of Cancer.

A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy.

M. Leach, P. Workman, I. Judson, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers.

H. Gevensleben, Y. Drew, R. Plummer, 2020, Cancer discovery.

Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations

Y. Drew, R. Plummer, N. Tunariu, 2016 .

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer

A. Harris, H. Earl, F. Balkwill, 2003, British Journal of Cancer.

Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients

R. Plummer, N. Tunariu, Juanita Lopez, 2015 .

A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)

P. Beale, I. Judson, F. Raynaud, 2003, British Journal of Cancer.

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.

N. Tunariu, Juanita Lopez, U. Banerji, 2020, The Lancet. Oncology.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

N. Tunariu, W. Brugger, D. Talbot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

454O A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)

A. Stathis, A. Alimonti, J. D. de Bono, 2022, Annals of Oncology.

Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.

H. Gevensleben, M. Hubank, Juanita Lopez, 2020, Cancer discovery.

Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.

N. Tunariu, Juanita Lopez, U. Banerji, 2017 .

A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

N. Tunariu, Juanita Lopez, U. Banerji, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions inKRASmutant cancers

G. Mills, C. Yap, Juanita Lopez, 2020 .

725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

N. Tunariu, U. Banerji, J. D. de Bono, 2021, Annals of Oncology.

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

N. Tunariu, A. Stathis, R. Ruddle, 2023, Nature.